Soroush Rais-Bahrami

Purpose of Review: To synthesize current evidence on the role of 29-MHz micro-ultrasound (microUS) in prostate cancer (PCa) detection and to define its position relative to multiparametric MRI (mpMRI) across the diagnostic pathway. We conducted a narrative review of prospective, comparative, and randomized studies, with clinically significant prostate cancer (csPCa) detection as the primary endpoint. Recent Findings: MicroUS provides ~ 70-µm axial resolution and enables real-time PRI-MUS–based risk stratification. Across head-to-head studies, microUS achieves diagnostic performance comparable to mpMRI. Evidence supports utility in biopsy-naïve patients, selected MRI-negative men with persistent clinical suspicion, repeat-biopsy settings, active surveillance, and local tumor staging, while combined mpMRI–microUS approaches have been shown to maximize yield of csPCa detection. Key limitations include operator dependence, interobserver variability, lack of validated biopsy-avoidance thresholds, and reduced sensitivity in anterior lesions. Summary: MicroUS is a practical, high-resolution platform that complements mpMRI and may enhance accessibility, efficiency, and precision in prostate cancer care.

Oxybutynin for hot flashes in men on androgen-deprivation therapy: interpreting the Alliance A222001 trial

Magnetic resonance imaging radiomics shows promise in guiding the selection of patients most likely to benefit from the use of immune checkpoint inhibitor therapy in patients with very‐high‐risk, nonmuscle‐invasive bladder cancer. This work arrives at a moment of rapid expansion in bladder‐sparing therapeutics, even as biomarker‐guided patient selection remains conspicuously absent across the field.